Latest News

(UroToday.com) Von Hippel-Lind (VHL) syndrome occurs because of hereditary inactivating genomic alterations in the VHL gene, resulting in a higher risk of developing renal cell carcinoma, retinal and CNS hemangioblastomas, and other tumors. Management of VHL syndrome-associated kidney neoplasms is challenging as tumors continue to arise despite surgical removal, which can result in renal insufficiency. […]

(UroToday.com) Avelumab is an anti-PD-L1 immune checkpoint inhibitor with a native IgG1 isotype backbone that can bind Fc receptors. In the JAVELIN 100 bladder trial, Avelumab first-line maintenance + best standard of care (BSC) significantly improved overall survival (OS) vs. (BSC) alone in patients with advanced urothelial carcinoma (UC) that had not progressed on first-line platinum-based […]

(UroToday.com)  Dr. Kilian Gust began his discussion of abstracts LBA27, 704MO, and 705MO with a discussion on historical efficacy rates of platinum therapy as first-line treatment for advanced urothelial carcinoma. Cisplatin-based regimens have an objective response rate (ORR) of 50% and median overall survival of 15 months, whereas carboplatin-based regimens have an ORR of 36% with […]

San Francisco, CA (UroToday.com) — The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.1

(UroToday.com) Sitravatinib is a tyrosine kinase inhibitor that inhibits multiple proteins including TAM (Tyro3, Axl, Mer) receptors, KIT and VEGFR2. Preclinical evidence suggests that sitravatinib may promote an anti-tumor immune response by reducing myeloid-derived suppressor cells and Tregs in the tumor microenvironment.

(UroToday.com) The current first-line standard of care therapy for advanced urothelial carcinoma patients with good performance status and kidney function is cisplatin-based chemotherapy. However, up to 50% of advanced urothelial carcinoma patients are not medically eligible for cisplatin therapy. Options, in this case, include carboplatin-based chemotherapy, or atezolizumab or pembrolizumab if patients have high levels of […]

(UroToday.com) Dr. Yohann Loriot presented the final results of the TROPHY-U-01 study, which was a phase 2 study of Sacituzumab Govitecan (anti-Trop-2) in metastatic urothelial carcinoma (mUC) patients who have progressed after platinum and checkpoint inhibitor therapy.1

(UroToday.com) The JAVELIN Bladder 100 trial, previously presented at ASCO 2020, was a phase 3 trial of platinum-eligible patients with advanced urothelial carcinoma who had stable disease after standard first line chemotherapy and then were randomized to avelumab maintenance therapy versus best supportive care. This trial demonstrated a significantly longer overall survival in patients who […]

(UroToday.com) In this discussion, Juergen Gschwend, MD, discussed Abstract 698O (patient-reported outcomes from IMvigor130), 699O (biomarker exploratory analyses for correlates of overall survival in JAVELIN Bladder 100), and LB24 (updated cohort 1 data for sacituzumab govitecan in heavily pre-treated metastatic urothelial carcinoma). He first offered a timeline of the evolution of systemic treatment options in […]

(UroToday.com) In this discussion, Juergen Gschwend, MD, discussed Abstract 698O (patient-reported outcomes from IMvigor130), 699O (biomarker exploratory analyses for correlates of overall survival in JAVELIN Bladder 100), and LB24 (updated cohort 1 data for sacituzumab govitecan in heavily pre-treated metastatic urothelial carcinoma). He first offered a timeline of the evolution of systemic treatment options in […]